Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 4, 2011, Pages 373-382

  Joya Galeana, J ^a   Fernandez, M ^a   Cervera, A ^a   Reyna, S ^a   Ghosh, S ^a   Triplitt, C ^a   Musi, N ^a   Defronzo, R A ^a   Cersosimo, E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Basal bolus therapy; Glycemic control; Muscle tissue inflammatory markers; Oral agents; Vascular dysfunction

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN 1; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN GLARGINE; INSULIN GLULISINE; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANGANESE SUPEROXIDE DISMUTASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; PIOGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTICLE; BLOOD FLOW; BLOOD VESSEL REACTIVITY; BODY COMPOSITION; BODY FAT; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CIRCULATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFECT; EVENING DOSAGE; FATTY ACID METABOLISM; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPEREMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; ISCHEMIA; LEAN BODY WEIGHT; MALE; MORNING DOSAGE; MUSCLE BIOPSY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; VASCULAR DISEASE; VASODILATATION;

ADULT; BODY MASS INDEX; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MEXICAN AMERICANS; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 79955725780     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1185     Document Type: Article

References (30)

1. American Heart Association. Heart Disease and Stroke Statistics. American Heart Association: Dallas, TX, 2003.
2. Kelley D, Reilly J, Venemann T, Mandarino LJ. Effect of insulin on skeletal muscle glucose storage, oxidation and glycolysis in humans. Am J Physiol 1990; 258: E923-E929.
3. Solini A, DeFronzo RA. Hypertension, cardiovascular disease, diabetes mellitus and diabetic nephropathy: role of insulin resistance. In The Kidney and Hypertension in Diabetes Mellitus, Mogensen C (ed.). Kluver Academic Publishers: Boston/Dordrecth/London, 1996; 61-74.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1900s. Nature 1993; 362: 801-809.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
6. The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Duckworth W, Abraira C, Moritz T, et al. for VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
8. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
9. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008; 31(1): 30-38.
10. DeFronzo RA, Tobin R, Andres R. The glucose clamp technique. A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 6: E214-E223.
11. Mandarino LJ, Wright K, Verity L, et al. Effect of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthetase. J Clin Invest 1987; 80: 655-663.
12. Steele R. Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 1959; 82: 420-430.
13. Correti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39: 257-265.
14. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
15. Musi N, Fuji N, Hirshman MF, et al. AMP-activated protein kinase (AMP-kinase) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 2001; 50: 921-927.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(Delta-Delta C (T) method. Methods 2001; 25: 402-408.
17. Hall PM, Cook JK, Gould BJ. An inexpensive, rapid and precise affinity chromatography method for the measurement of glycosylated hemoglobins. Ann Clin Biochem 1983; 20: 129-135.
18. Herbert V, Lau K, Gotlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-1384.
19. Zaitseva I, Ajmal M, Cersosimo E. Application of high-performance liquid chromatography of plasma fatty acids as their phenacyl esters to evaluate splanchnic and renal fatty acid balance in vivo. J Chromatograph B 1999; 727: 15-22.
20. Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi E, Mehta JL. Alterations in serum intercellular adhesion molecule-1 and L-selectin levels in patients with coronary artery disease. Circulation 1996; 88: 1-8.
21. Yamauchi T, Kamon J, Ito Y. Cloning of adiponectin receptors that mediate anti-diabetic metabolic effects. Nature 2003; 423: 762-769.
22. Taskinen M. Hyperlipidemia in diabetes. Bailleres Clin Endocrinol Metab 2001; 4: 743-775.
23. Koshiyama H, Shimono D, Kuwamura N. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
24. Nissen SE, Nichols SJ, Wolski K, et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes (the periscope randomized controlled trial). JAMA 2008; 299: 1561-1573.
25. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
26. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
27. Costanzo P, Perrone-Filardi P, Enrico V, et al. Does carotid intima-media thickness regression predict reduction in cardiovascular events? J Am Coll Cardiol 2010; 56: 2006-2020.
28. Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 2123-2130.
29. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005; 54: 1640-1648.
30. Lundman P, Eriksson M, Schenck-Gustafson K. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary artery disease. Circulation 1997; 96: 3266-3268.